← FDA DRUG APPROVALS

FDA NDA · NDA020469

VANCENASE AQ

Sponsor: SCHERING

APPLICATION
NDA020469
TYPE
NDA
ORIGINAL APPROVAL
1996-06-26
LATEST ACTION
2002-06-11
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Discontinued

Products

VANCENASE AQDiscontinued
BECLOMETHASONE DIPROPIONATE MONOHYDRATE EQ 0.084MG DIPROP/SPRAY · SPRAY, METERED · NASAL

Approval history

2002-06-11Manufacturing (CMC) · Supplement 7 · standardAP
2000-08-30Manufacturing (CMC) · Supplement 8 · standardAP
1998-07-28Manufacturing (CMC) · Supplement 6 · standardAP
1997-03-14Manufacturing (CMC) · Supplement 1 · standardAP
1997-02-13Labeling · Supplement 2 · standardAP
1997-02-13Labeling · Supplement 3 · standardAP
1996-06-26Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →